Tumores Gastrintestinais
Estudo randomizado | Adjuvante S-1 comparado com observação no câncer ressecado do trato biliar
23 Jan, 2023 | 13:17hAdjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
New @TheLancet – Nakachi et al – Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial https://t.co/E6y7a9dWNf#gitwitter #biliarytractcancer #onctwitter @OncoAlert #JCOG pic.twitter.com/WEBFXjIWce
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 20, 2023
Estudo de braço único fase 2 | Futibatinibe para colangiocarcinoma intra-hepático rearranjado por FGFR2
23 Jan, 2023 | 13:13hFutibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg
— NEJM (@NEJM) January 19, 2023
Estudo de coorte | Hemicolectomia vs. apendicectomia para pacientes com tumores neuroendócrinos do apêndice com 1 a 2 cm de tamanho
23 Jan, 2023 | 13:12hHemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário: Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors – The ASCO Post
Revisão | Gastroenterologia intervencionista na oncologia.
13 Dez, 2022 | 15:15hInterventional gastroenterology in oncology – CA: A Cancer Journal for Clinicians
Seguimento pós-estudo | Bursectomia vs. omentectomia isolada para câncer gástrico ressecável.
13 Dez, 2022 | 14:59hFive-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001) – British Journal of Surgery (link para o resumo – $ para o texto completo)
Benefícios de 15 anos do rastreamento por sigmoidoscopia na incidência e na mortalidade de câncer colorretal: análise agrupada de estudos randomizados.
17 Out, 2022 | 13:34h15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: A Pooled Analysis of Randomized Trials – Annals of Internal Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: One sigmoidoscopy significantly reduces long-term CRC incidence in both men and women – American College of Physicians
Conteúdos relacionados:
RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
ACP Guideline: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (se o acesso a este link for pago, tente este em PMC)
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Comentário no Twitter
A pooled analysis evaluating 15-yr effect of sigmoidoscopies found that receiving 1 #sigmoidoscopy significantly reduces long-term incidence of CRC in men and women: https://t.co/QXj5VRMHeo pic.twitter.com/s82sOJmBzr
— Annals of Int Med (@AnnalsofIM) October 11, 2022
Estudo randomizado | Efeito do rastreamento com colonoscopia sobre os riscos de câncer colorretal e morte relacionada.
17 Out, 2022 | 12:59hEffect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentários:
In gold-standard trial, invitation to colonoscopy reduced cancer incidence but not death – STAT
New study examines the effectiveness of colonoscopies – CNN
Podcast | Pólipos, polipectomia e vigilância.
6 Out, 2022 | 12:36hPolyps, polypectomy & surveillance with Dr. Jennifer Maranki – The Curbsiders
Estudo de coorte | A taxa de detecção de adenoma após teste fecal imunoquímico (fecal immunochemical test – FIT) positivo está associada a risco de câncer colorretal no intervalo pós-colonoscopia.
6 Out, 2022 | 12:34hAdenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test–Based Screening: A Population-Based Cohort Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)
Comentários:
Adenoma Detection Rate Tied to CRC Risk After Positive FIT – HealthDay
Comentário no Twitter
New from @ErasmusMC: endoscopists performing colonoscopy in FIT-based screening programs should aim for higher ADRs compared w/ programs that use colonoscopy as primary screening intervention: https://t.co/Fob1gxXF1i pic.twitter.com/y6qoAkOrT9
— Annals of Int Med (@AnnalsofIM) September 30, 2022
Estudo de coorte | Calculadora clínica para câncer retal pode estimar a recorrência após terapia neoadjuvante com ou sem cirurgia.
3 Out, 2022 | 12:46hComentário convidado: A Clinical Calculator in the Era of Nonoperative Management for Rectal Cancer—How Should We Intensify or Deescalate Surveillance? – JAMA Network Open